4.6 Article

Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency

期刊

JOURNAL OF CLINICAL IMMUNOLOGY
卷 42, 期 8, 页码 1626-1637

出版社

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-022-01319-0

关键词

Common variable immunodeficiency; hepatopathy; portal hypertension; diagnosis; nodular regenerative hyperplasia

资金

  1. Deutsche Forschungsgemeinschaft [SFB 1160 IMPATH]
  2. EU [634413, 777377]
  3. Projekt DEAL

向作者/读者索取更多资源

Portal hypertension, a manifestation in some CVID patients, is usually not associated with liver cirrhosis. Spleen enlargement and elevated liver stiffness have been identified as markers for further evaluation of portal hypertension in CVID, but better liquid biomarkers are needed for diagnosing this serious complication.
Timely detection of portal hypertension as a manifestation in a subgroup of patients with common variable immunodeficiency (CVID) represents a challenge since it is usually not associated with liver cirrhosis. To identify relevant markers for portal hypertension, we evaluated clinical history, laboratory parameters, and abdominal ultrasound including liver elastography and biomarkers of extracellular matrix formation. Twenty seven (6%) of 479 CVID patients presented with clinically significant portal hypertension as defined by either the presence of esophageal varices or ascites. This manifestation occurred late during the course of the disease (11.8 years after first diagnosis of CVID) and was typically part of a multiorgan disease and associated with a high mortality (11/27 patients died during follow up). The strongest association with portal hypertension was found for splenomegaly with a longitudinal diameter of > 16 cm. Similarly, most patients presented with a liver stiffness measurement (LSM) of above 6.5 kPa, and a LSM above 20 kPa was always indicative of manifest portal hypertension. Additionally, many laboratory parameters including Pro-C4 were significantly altered in patients with portal hypertension without clearly increasing the discriminatory power to detect non-cirrhotic portal hypertension in CVID. Our data suggest that a spleen size above 16 cm and an elevated liver stiffness above 6.5 kPa should prompt further evaluation of portal hypertension and its sequelae, but earlier and better liquid biomarkers of this serious secondary complication in CVID are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据